Understanding the Many Faces of Pseudobulbar Affect

Slides:

Advertisements

Similar presentations

Articulating the Unmet Need in the Diagnosis and Treatment of Pseudobulbar Affect: Prevalence of the Condition and Limitations of Existing Therapies Ursula.

Advertisements

Dry Eye Disease: Pathophysiology, Symptoms, Intervention

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Current Management and Future Options for Tardive Dyskinesia

New Psoriasis Treatments

Psoriatic Arthritis.

Exploring the Spectrum of Excessive Daytime Sleepiness

Progression After Cancer Immunotherapy in Advanced NSCLC

Reducing Postoperative Ileus

Clues to a Diagnosis: A Focus on Light-Chain Amyloidosis

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Advances in Dry Eye.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Multidisciplinary Perspectives on Interstitial Lung Diseases

Improving Outcomes in OSA

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

Pseudobulbar Affect or Psychiatric Condition?

Impactful Data in TD That Can Guide Treatment Decisions

New Recommendations on How to Stage Hidradenitis Suppurativa

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Advancing Care Across the Spectrum of Pancreatic Cancer

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Talking With Your Patients About Excessive Sweating

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Exploring Neurostimulation

Novel Concepts in the Management of RCC

From Adjuvant to Metastatic in Melanoma

Why New Treatments for Hyperhidrosis Should Be on Your Radar

The Psychiatrist's Role in Tardive Dyskinesia

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

HAE Prophylaxis.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Presentation transcript:

Understanding the Many Faces of Pseudobulbar Affect

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

What Is PBA?

Pathophysiology of PBA

Essential Criteria for PBA

Supportive Criteria for PBA

Differential Diagnosis of PBA

Prevalence of PBA Symptoms in Published Studies

Prevalence of PBA in PRISM

Impact of PBA on QoL According to Neurologic Condition

Decreased QoL in Veterans With TBI and PBA

STAR Trial Design

STAR Trial Results

PRISM II Design

PRISM II Results

PBA Recognition

PBA Recognition (cont)

Treatment Options

Treatment Considerations With DM/Q

Treatment Considerations With TCAs and SSRIs

Conclusions

Abbreviations